Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Receives $463.13 Consensus Target Price from Brokerages

Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) have been given a consensus rating of “Moderate Buy” by the twenty-six ratings firms that are currently covering the company, Marketbeat Ratings reports. Six investment analysts have rated the stock with a hold recommendation, eighteen have given a buy recommendation and two have assigned a strong buy recommendation to the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $463.1326.

A number of research analysts have commented on the stock. Chardan Capital reissued a “buy” rating and set a $425.00 target price on shares of Alnylam Pharmaceuticals in a research report on Wednesday, March 25th. Weiss Ratings raised shares of Alnylam Pharmaceuticals from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Monday, May 4th. Needham & Company LLC cut their target price on shares of Alnylam Pharmaceuticals from $529.00 to $510.00 and set a “buy” rating on the stock in a research report on Thursday, February 12th. Truist Financial cut their target price on shares of Alnylam Pharmaceuticals from $515.00 to $505.00 and set a “buy” rating on the stock in a research report on Monday, April 13th. Finally, Freedom Capital raised shares of Alnylam Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, February 17th.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, insider Melissa Mclaughlin sold 2,286 shares of the firm’s stock in a transaction dated Monday, April 6th. The shares were sold at an average price of $330.42, for a total transaction of $755,340.12. Following the transaction, the insider owned 9,443 shares of the company’s stock, valued at approximately $3,120,156.06. This trade represents a 19.49% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Pushkal Garg sold 1,775 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Tuesday, March 3rd. The stock was sold at an average price of $319.74, for a total transaction of $567,538.50. Following the completion of the transaction, the executive vice president directly owned 23,406 shares in the company, valued at approximately $7,483,834.44. The trade was a 7.05% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 21,255 shares of company stock worth $6,930,337. 0.86% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the company. Glenmede Trust Co. NA grew its position in shares of Alnylam Pharmaceuticals by 8.3% in the 1st quarter. Glenmede Trust Co. NA now owns 731 shares of the biopharmaceutical company’s stock worth $242,000 after buying an additional 56 shares during the last quarter. Groupama Asset Managment grew its position in shares of Alnylam Pharmaceuticals by 2.5% in the 1st quarter. Groupama Asset Managment now owns 36,767 shares of the biopharmaceutical company’s stock worth $12,165,000 after buying an additional 889 shares during the last quarter. Segall Bryant & Hamill LLC purchased a new position in shares of Alnylam Pharmaceuticals in the 1st quarter worth approximately $641,000. Janus Henderson Group PLC grew its position in shares of Alnylam Pharmaceuticals by 7.8% in the 1st quarter. Janus Henderson Group PLC now owns 147,089 shares of the biopharmaceutical company’s stock worth $48,661,000 after buying an additional 10,664 shares during the last quarter. Finally, Oddo BHF Asset Management Sas grew its position in shares of Alnylam Pharmaceuticals by 9.6% in the 1st quarter. Oddo BHF Asset Management Sas now owns 33,013 shares of the biopharmaceutical company’s stock worth $10,923,000 after buying an additional 2,880 shares during the last quarter. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Trading Down 0.7%

Shares of ALNY opened at $295.50 on Wednesday. The company has a debt-to-equity ratio of 0.94, a current ratio of 3.13 and a quick ratio of 3.06. The firm has a market capitalization of $39.45 billion, a price-to-earnings ratio of 80.74 and a beta of 0.31. The company has a 50-day moving average of $310.41 and a 200 day moving average of $357.09. Alnylam Pharmaceuticals has a 1-year low of $284.28 and a 1-year high of $495.55.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.99 EPS for the quarter, beating analysts’ consensus estimates of $0.87 by $1.12. The business had revenue of $1.17 billion for the quarter, compared to the consensus estimate of $1.12 billion. Alnylam Pharmaceuticals had a net margin of 11.72% and a return on equity of 85.76%. The company’s revenue for the quarter was up 96.4% on a year-over-year basis. During the same quarter last year, the firm posted ($0.44) EPS. On average, research analysts expect that Alnylam Pharmaceuticals will post 7.36 EPS for the current year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.